Filtered By:
Condition: Ischemic Stroke
Management: Budgets

This page shows you your search results in order of date.

Order by Relevance | Date

Total 18 results found since Jan 2013.

Mechanical Thrombectomy for Acute Ischemic Stroke Due to Large Vessel Occlusion in Argentina: An Economic Analysis
This study was designed to estimate the economic value and the budget impact of incorporating MT after thrombolysis, simulating scenarios from Argentinian compulsory social health insurance (Obras Sociales) and private insurances (Empresas de Medicina Prepaga).
Source: Journal of Stroke and Cerebrovascular Diseases - June 15, 2022 Category: Neurology Authors: Pedro Lylyk, Juan Cirio, Carlos Toranzo, Eleonora Aiello, Juan Valencia, Daniela Paredes-Fern ández Source Type: research

PND36 Budget Impact Analysis of the Incorporation of Mechanical Thrombectomy with Stent Retrievers after Thrombolysis in Ischemic-Stroke with Large Vessel Occlusion in Programa De Atencion medica Integral Pami in Argentina
Stroke is responsible for mortality and long-term disability in Argentina. Available treatments for stroke due to Large Vessel Occlusion (LVO) are Thrombolysis (IV-tPA) and Mechanical Thrombectomy (MT). However, despite its clinical benefits, MT coverage in Argentina and PAMI is low. A Budget-Impact Analysis (BIA) was conducted to estimate the financial impact of incorporating MT after IV-TPA in PAMI for the elderly.
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: P. Lylyk, J. Cirio, C. Toranzo, E.C. Aiello, D. Paredes, J. Valencia Source Type: research

PND28 Budget Impact Analysis of the Incorporation of Mechanical Thrombectomy with Stent Retrievers after Thrombolysis in Ischemic-Stroke with Large Vessel Occlusion in Obras Sociales and Empresas De Medicina Prepaga in Argentina
Stroke is associated with high clinical and economic burden of disease. Available treatments for stroke due to Large Vessel Occlusion (LVO) in Argentina are Thrombolysis (IV-tPA) and Mechanical Thrombectomy (MT). Despite its clinical benefits, MT coverage in Argentina is low. A Budget-Impact Analysis (BIA) was conducted to estimate the financial impact of incorporating MT after IV-TPA in Obras Sociales and Empresas de Medicina Prepaga (EMP) in Argentina.
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: P. Lylyk, J. Cirio, C. Toranzo, E.C. Aiello, D. Paredes, J. Valencia Source Type: research

TCT 2017: Boston Scientific touts lowered hemorrhagic stroke rate, cost for patients in Watchman studies
Boston Scientific (NYSE:BSX) today released combined 5-year outcomes data from both the Prevail and Protect-AF study of its Watchman left atrial appendage closure device, touting it as a safe and effective an alternative to long-term warfarin therapy for patients with non-valvular atrial fibrillation. Five-year data from the Prevail study was published online today in the Journal of the American College of Cardiology. In both trials, the Marlborough, Mass.-based company compared the Watchman device to warfarin treatment for stroke prevention in patients with non-valvular AF with follow-ups out to five years. A combined an...
Source: Mass Device - November 2, 2017 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Clinical Trials Boston Scientific Source Type: news

Budget Impact Analysis (BIA) Of Mechanical Thrombectomy In Acute Phase Of Ischemic Stroke (AIS)
To estimate financial consequences of reimbursement of mechanical thrombectomy (MT) using a stent retriever in patients with AIS in Poland.
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: M Pochopien, T Fundament, G Niesyczynski, A Lembas, R Plisko Source Type: research

Budget Impact of Alteplase In Treatment of Acute Ischemic Stroke In Turkey
Cerebrovascular diseases are the sixth cause of total DALYs in Turkey and the Turkish Social Security Institution (SSI) faces a challenge on reimbursement decisions for treatment. Alteplase is a recombinant human tissue plasminogen activator indicated for treatment of acute ischemic stroke (AIS). Clinical trials have proved efficacy in reducing 90-day disability measured by the Modified Rankin Score (mRS) if administered within 4,5 hours of onset of symptoms. The agent is used as an addition to Standard of Care (SoC).
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: M Tatar, A Şentürk, E Tetik, L Yıldız, J Cheynel Source Type: research

MassDevice.com +5 | The top 5 medtech stories for September 15, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. FDA cuts could threaten medtech innovation: Here’s why The Trump administration’s proposed federal budget could hurt the speed and quality of FDA review times, says a top expert at Musculoskeletal Clinical Regulatory Advise...
Source: Mass Device - September 15, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Mind the Treatment Gap
getty images/ istock photoBy Vani S. Kulkarni and Raghav GaihaPHILADELPHIA AND NEW DELHI, Apr 14 2017 (IPS)Implementation of the Mental Healthcare Act will require a restructuring of health-care services The Mental Healthcare Bill, 2016, which was passed in the Lok Sabha on March 27, 2017, has been hailed as a momentous reform. According to the Bill, every person will have the right to access mental health care operated or funded by the government; good quality and affordable health care; equality of treatment and protection from inhuman practices; access to legal services; and right to complain against coercion and cruelt...
Source: IPS Inter Press Service - Health - April 14, 2017 Category: Global & Universal Authors: Vani Kulkarni and Raghav Gaiha Tags: Asia-Pacific Development & Aid Gender Gender Violence Headlines Health Human Rights Women's Health Source Type: news

4 Key Insights When Raising Money for Your Medtech Startup: Interview with Bruce Shook, CEO of Intact Vascular
Welcome to the Medsider interview series, a regular feature at MassDevice. All interviews are conducted by Scott Nelson, Founder of Medsider and Group Director for WCG. We hope you enjoy them! Bruce Shook joined Intact Vascular in 2014 as President and CEO. A highly-experienced, medical device executive with more than 30 years of industry experience, Bruce was previously Co-founder, Director, President, and CEO of Neuronetics, which is a privately held medical device company that markets a non-invasive brain stimulation technology for the treatment of depression. Previously, Shook was Co-founder, Director, President, an...
Source: Mass Device - February 27, 2017 Category: Medical Equipment Authors: Danielle Kirsh Tags: Blog medsider Source Type: news

Prevention and treatment of cardiovascular disease in Ethiopia: a cost-effectiveness analysis
The coverage of prevention and treatment strategies for ischemic heart disease and stroke is very low in Ethiopia. In view of Ethiopia ’s meager healthcare budget, it is important to identify the most cost-effe...
Source: Cost Effectiveness and Resource Allocation - August 12, 2016 Category: Health Management Authors: Mieraf Taddesse Tolla, Ole Frithjof Norheim, Solomon Tessema Memirie, Senbeta Guteta Abdisa, Awel Ababulgu, Degu Jerene, Melanie Bertram, Kirsten Strand, St éphane Verguet and Kjell Arne Johansson Source Type: research

Pharmacoeconomic Analysis of Naftidrofuryl for Ischemic Stroke Treatment
Perform the pharmacoeconomic analysis of including naftidrofuryl into the Russian standards for treatment and rehabilitation of patients suffering from ischemic stroke by means of performing Cost Minimization Analysis (CMA) and Budget Impact Analysis (BIA).
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: D Belousov, A Cheberda Source Type: research

Budget Impact Analysis of The Use of Alteplase In The Treatment of Acute Ischaemic Stroke In Mexico
To estimate the economic impact of the use of alteplase versus best supportive care (BSC) in patients with acute ischemic stroke in Mexico.
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: JL Huicochea-Bartelt, E Palacios, L Zapata, S Herran Tags: CARDIOVASCULAR DISORDERS – Cost Studies Source Type: research

Budget Impact Analysis of Cerebrolysin In The Treatment of Acute Ischemic Stroke of Moderate and Severe Degrees of Severity In The Russian Federation
To conduct budget impact analysis of neurotrophic and neuroprotective drug cerebrolysin with standard therapy compared to standard therapy only of ischemic stroke of moderate and severe degrees of severity according to the Russian healthcare system.
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: A Kulikov, G Abdrashitova Source Type: research

The Impact of Outpatient Rehabilitation Medicare Reimbursement Caps on Utilization and Cost of Rehabilitation Care after Ischemic Stroke: Do Caps contain costs?
To estimate the proportion of ischemic stroke patients who fall within and above the total outpatient rehabilitation caps before and after the Balanced Budget Act of 1997 (BBA 1997) took effect. In addition, estimate the cost of post-stroke outpatient rehabilitation cost and resource utilization in these patients prior to and after the implementation of the caps.
Source: Archives of Physical Medicine and Rehabilitation - July 28, 2015 Category: Rehabilitation Authors: Annie N. Simpson, Heather S. Bonilha, Abby S. Kazley, James S. Zoller, Kit N. Simpson, Charles Ellis Source Type: research

Impact of Outpatient Rehabilitation Medicare Reimbursement Caps on Utilization and Cost of Rehabilitation Care After Ischemic Stroke: Do Caps Contain Costs?
To estimate the proportion of patients with ischemic stroke who fall within and above the total outpatient rehabilitation caps before and after the Balanced Budget Act of 1997 took effect; and to estimate the cost of poststroke outpatient rehabilitation cost and resource utilization in these patients before and after the implementation of the caps.
Source: Archives of Physical Medicine and Rehabilitation - July 28, 2015 Category: Rehabilitation Authors: Annie N. Simpson, Heather S. Bonilha, Abby S. Kazley, James S. Zoller, Kit N. Simpson, Charles Ellis Tags: Original research Source Type: research